218 related articles for article (PubMed ID: 11591826)
1. Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells.
Ma Z; Webb DJ; Jo M; Gonias SL
J Cell Sci; 2001 Sep; 114(Pt 18):3387-96. PubMed ID: 11591826
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth.
Webb DJ; Thomas KS; Gonias SL
J Cell Biol; 2001 Feb; 152(4):741-52. PubMed ID: 11266465
[TBL] [Abstract][Full Text] [Related]
3. Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion.
Webb DJ; Nguyen DH; Gonias SL
J Cell Sci; 2000 Jan; 113 ( Pt 1)():123-34. PubMed ID: 10591631
[TBL] [Abstract][Full Text] [Related]
4. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
[TBL] [Abstract][Full Text] [Related]
5. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner.
Nguyen DH; Catling AD; Webb DJ; Sankovic M; Walker LA; Somlyo AV; Weber MJ; Gonias SL
J Cell Biol; 1999 Jul; 146(1):149-64. PubMed ID: 10402467
[TBL] [Abstract][Full Text] [Related]
6. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Xue A; Xue M; Jackson C; Smith RC
Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
[TBL] [Abstract][Full Text] [Related]
7. siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells.
Subramanian R; Gondi CS; Lakka SS; Jutla A; Rao JS
Int J Oncol; 2006 Apr; 28(4):831-9. PubMed ID: 16525631
[TBL] [Abstract][Full Text] [Related]
8. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility.
Nguyen DH; Hussaini IM; Gonias SL
J Biol Chem; 1998 Apr; 273(14):8502-7. PubMed ID: 9525964
[TBL] [Abstract][Full Text] [Related]
9. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling.
Aguirre Ghiso JA; Kovalski K; Ossowski L
J Cell Biol; 1999 Oct; 147(1):89-104. PubMed ID: 10508858
[TBL] [Abstract][Full Text] [Related]
10. Mitogenic signaling of urokinase receptor-deficient kidney fibroblasts: actions of an alternative urokinase receptor and LDL receptor-related protein.
Zhang G; Cai X; López-Guisa JM; Collins SJ; Eddy AA
J Am Soc Nephrol; 2004 Aug; 15(8):2090-102. PubMed ID: 15284295
[TBL] [Abstract][Full Text] [Related]
11. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
Mahanivong C; Yu J; Huang S
Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
[TBL] [Abstract][Full Text] [Related]
12. Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator.
Jo M; Thomas KS; Marozkina N; Amin TJ; Silva CM; Parsons SJ; Gonias SL
J Biol Chem; 2005 Apr; 280(17):17449-57. PubMed ID: 15728176
[TBL] [Abstract][Full Text] [Related]
13. The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro.
Webb DJ; Nguyen DH; Sankovic M; Gonias SL
J Biol Chem; 1999 Mar; 274(11):7412-20. PubMed ID: 10066806
[TBL] [Abstract][Full Text] [Related]
14. Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling.
Jo M; Thomas KS; Wu L; Gonias SL
J Biol Chem; 2003 Nov; 278(47):46692-8. PubMed ID: 12963722
[TBL] [Abstract][Full Text] [Related]
15. uPAR expression under hypoxic conditions depends on iNOS modulated ERK phosphorylation in the MDA-MB-231 breast carcinoma cell line.
Yoon SY; Lee YJ; Seo JH; Sung HJ; Park KH; Choi IK; Kim SJ; Oh SC; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
Cell Res; 2006 Jan; 16(1):75-81. PubMed ID: 16467878
[TBL] [Abstract][Full Text] [Related]
16. Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity.
Huang S; New L; Pan Z; Han J; Nemerow GR
J Biol Chem; 2000 Apr; 275(16):12266-72. PubMed ID: 10766865
[TBL] [Abstract][Full Text] [Related]
17. Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated protein kinase 2.
Tran H; Maurer F; Nagamine Y
Mol Cell Biol; 2003 Oct; 23(20):7177-88. PubMed ID: 14517288
[TBL] [Abstract][Full Text] [Related]
18. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-beta1 integrin complex in colon cancer cells.
Ahmed N; Oliva K; Wang Y; Quinn M; Rice G
Br J Cancer; 2003 Jul; 89(2):374-84. PubMed ID: 12865932
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor-dependent and -independent cell-signaling pathways originating from the urokinase receptor.
Jo M; Thomas KS; O'Donnell DM; Gonias SL
J Biol Chem; 2003 Jan; 278(3):1642-6. PubMed ID: 12426305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
